The global research antibodies market (including reagents) is projected to reach USD 12.60 Billion by 2022 from USD 9.33 Billion in 2017, growing at a CAGR of 6.2% during the forecast period. Factors such as the increasing R&D activities and expenditure in the life science industry, increasing funding for proteomics research and drug discovery, and growing collaboration between industries and academic institutes are the key drivers of the market.
The report analyzes the global research antibodies market (including reagents) by product, technology, application, end user, and region. Based on product, the market is segmented into reagents and antibodies. The reagents segment accounted for the major share of the research antibodies market (including reagents) in 2016. This can be attributed to the fact that a large number of reagents are used in various routine assays and techniques. Furthermore, based on type, the reagents market has been further segmented into media & sera, stains & dyes, fixatives, buffers, probes, solvents, enzymes, and others (controls, stabilizers, and diluents). The media & sera segment is expected to dominate the market in 2016 due to its high usage in all types of assays, culture procedures, and techniques.

The antibodies market has also been segmented on the basis of type, source, and research area. Based on type, the research antibodies market is segmented into primary antibodies and secondary antibodies. In 2016, the primary antibodies is expected to dominate the market due to its high adoption in numerous types of assay formats, including western blotting, ELISA, immunoprecipitation, and IHC. These antibodies provide high specificity, sensitivity, and affinity; which further drives their high adoption. On the basis of source, the antibodies market has been segmented into mice, rabbit, and other animals (chickens, goats, rats, guinea pigs, hamsters, and sheep). The mice segment dominated the market in 2016. Based on research area, the antibodies market has been segmented into oncology, infectious diseases, immunology, neurobiology, stem cell, and others (epigenetics, toxicology, and cardiovascular diseases). The oncology segmented held the largest share of the market in 2016 due to the fact that cancer is the leading cause of deaths worldwide, which has driven the focus on its early detection and treatment. Moreover, understanding the cause and risk factors of cancer also form an important area of cancer research.

Based on technology, the research antibodies market is segmented into western blotting, flow cytometry, ELISA, immunohistochemistry, immunofluorescence, immunoprecipitation, and others (electrophoresis, bio-imaging, and microarrays). The western blotting segment accounted for the largest share of the global research antibodies market in 2016. Its ability to quantify as little as 0.1 nanograms of protein in a sample with high specificity makes it an indispensable tool in proteomic research; this is the key factor driving market growth.

On the basis of application, the research antibodies market is segmented into proteomics, drug development, and genomics. In 2016, the proteomics segment dominated the applications market. This large share can be attributed to the high deployment of proteomic-based approaches in disease profiling, increasing government funding, rising demand of personalized & protein therapeutics, and increasing R&D expenditure.

Based on end user, the market has been segmented into pharmaceutical & biotechnological companies, academic & research institutes, and contract research organizations. In 2016, the pharmaceutical and biotechnological companies accounted for the largest share of the research antibodies market. This can be attributed to the high uptake of research-specific antibodies in the drug discovery and development process, along with the increasing use of these research tools in the proteomics research sector.

Geographically, the global research antibodies market is segmented into Europe, Asia-Pacific, North America, Latin America, and the Middle East & Africa. North America holds the largest share of this market. However, the Asia-Pacific region is expected to witness the highest CAGR during the forecast period of 2017 to 2022. The growth of this segment can be attributed to the growing proteomics and genomics research & increasing research funding, increasing investments by pharmaceutical and biotechnology companies, and growing awareness of personalized therapeutics.

The global research antibodies and reagent market is characterized by a large number of players. The market is highly competitive in nature and is dominated by Thermo Fisher Scientific, Inc. (U.S.), Merck Group (Germany), Abcam plc (U.K.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cell Signaling Technology, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (U.S.), GenScript (U.S.), PerkinElmer, Inc. (U.S.), Lonza (Switzerland), and BioLegend, Inc. (U.S.). Key players in the market are pursuing several organic and inorganic growth strategies such as product launches, expansions, acquisitions, and agreements to garner larger shares of the market. During 2013 to 2017, companies adopted product launches as their major growth strategy followed by acquisitions.